-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Analyzing BioAffinity Technologies (NASDAQ:BIAF) & ICON Public (NASDAQ:ICLR)
Analyzing BioAffinity Technologies (NASDAQ:BIAF) & ICON Public (NASDAQ:ICLR)
bioAffinity Technologies (NASDAQ:BIAF – Get Rating) and ICON Public (NASDAQ:ICLR – Get Rating) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, analyst recommendations and risk.
Insider & Institutional Ownership
91.3% of ICON Public shares are held by institutional investors. 44.0% of ICON Public shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Get bioAffinity Technologies alerts:Analyst Ratings
This is a summary of current recommendations and price targets for bioAffinity Technologies and ICON Public, as provided by MarketBeat.com.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
bioAffinity Technologies | 0 | 0 | 0 | 0 | N/A |
ICON Public | 0 | 3 | 7 | 0 | 2.70 |
Profitability
This table compares bioAffinity Technologies and ICON Public's net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
bioAffinity Technologies | N/A | N/A | N/A |
ICON Public | 2.77% | 10.54% | 4.91% |
Earnings & Valuation
This table compares bioAffinity Technologies and ICON Public's revenue, earnings per share and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
bioAffinity Technologies | N/A | N/A | N/A | N/A | N/A |
ICON Public | $5.48 billion | 2.73 | $153.18 million | $2.52 | 72.93 |
ICON Public has higher revenue and earnings than bioAffinity Technologies.
Summary
ICON Public beats bioAffinity Technologies on 8 of the 8 factors compared between the two stocks.
About bioAffinity Technologies
(Get Rating)
bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat cancer at the cellular level. The company was founded in 2014 and is based in San Antonio, Texas.
About ICON Public
(Get Rating)
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It offers clinical development services, including early development, patient recruitment and retention, strategy and analytics, late phase research, data and technology solution, and consulting and analytics services. The company's clinical development services also comprise medical imaging, clinical research and laboratory services, project management, site monitoring and management services, data management, biostatistics and programming, medical writing and publishing, medical affair, endpoint adjudication/data monitoring committees, pharmacovigilance, interactive response technologies, clinical supplies management, strategic regulatory, medical communication, and consulting and advisory services. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. The company was incorporated in 1990 and is headquartered in Dublin, Ireland.
Receive News & Ratings for bioAffinity Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bioAffinity Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
bioAffinity Technologies (NASDAQ:BIAF – Get Rating) and ICON Public (NASDAQ:ICLR – Get Rating) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, analyst recommendations and risk.
生物親和科技(納斯達克:BIAF-GET評級)和圖標公開(納斯達克:ICLR-GET評級)都是醫療公司,但哪隻股票更好?我們將根據兩家公司的盈利能力、機構所有權、估值、收益、股息、分析師建議和風險等方面的實力進行比較。
Insider & Institutional Ownership
內部人與機構所有權
91.3% of ICON Public shares are held by institutional investors. 44.0% of ICON Public shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
91.3%的ICON公眾股票由機構投資者持有。44.0%的ICON公眾股票由公司內部人士持有。強大的機構持股表明,捐贈基金、對衝基金和大型基金管理公司相信,一隻股票有望實現長期增長。
Analyst Ratings
分析師評級
This is a summary of current recommendations and price targets for bioAffinity Technologies and ICON Public, as provided by MarketBeat.com.
這是由MarketBeat.com提供的BioAffity Technologies和ICON Public的當前建議和目標價的摘要。
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
bioAffinity Technologies | 0 | 0 | 0 | 0 | N/A |
ICON Public | 0 | 3 | 7 | 0 | 2.70 |
銷售評級 | 保持評級 | 購買評級 | 強勁的買入評級 | 評級分數 | |
生物親和技術 | 0 | 0 | 0 | 0 | 不適用 |
圖標公共 | 0 | 3 | 7 | 0 | 2.70 |
Profitability
盈利能力
This table compares bioAffinity Technologies and ICON Public's net margins, return on equity and return on assets.
下表比較了BioAffity Technologies和ICON Public的淨利潤率、股本回報率和資產回報率。
Net Margins | Return on Equity | Return on Assets | |
bioAffinity Technologies | N/A | N/A | N/A |
ICON Public | 2.77% | 10.54% | 4.91% |
淨利潤率 | 股本回報率 | 資產回報率 | |
生物親和技術 | 不適用 | 不適用 | 不適用 |
圖標公共 | 2.77% | 10.54% | 4.91% |
Earnings & Valuation
收益與估值
This table compares bioAffinity Technologies and ICON Public's revenue, earnings per share and valuation.
該表格比較了BioAffity Technologies和ICON Public的收入、每股收益和估值。
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
bioAffinity Technologies | N/A | N/A | N/A | N/A | N/A |
ICON Public | $5.48 billion | 2.73 | $153.18 million | $2.52 | 72.93 |
總收入 | 價格/銷售額比 | 淨收入 | 每股收益 | 市盈率 | |
生物親和技術 | 不適用 | 不適用 | 不適用 | 不適用 | 不適用 |
圖標公共 | 54.8億美元 | 2.73 | 1.5318億美元 | $2.52 | 72.93 |
ICON Public has higher revenue and earnings than bioAffinity Technologies.
圖標公共公司的收入和收益比生物親和技術公司高。
Summary
摘要
ICON Public beats bioAffinity Technologies on 8 of the 8 factors compared between the two stocks.
在兩隻股票之間的8個因素中,ICON Public在8個因素上擊敗了BioAffity Technologies。
About bioAffinity Technologies
關於生物親和技術
(Get Rating)
(獲取評級)
bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat cancer at the cellular level. The company was founded in 2014 and is based in San Antonio, Texas.
生物親和技術公司是一家生物技術公司,致力於開發非侵入性診斷測試和靶向癌症療法。該公司提供CyPath肺部診斷測試,用於早期發現肺癌。它還研究在細胞水平上治療癌症的靶向療法。該公司成立於2014年,總部設在德克薩斯州聖安東尼奧。
About ICON Public
關於圖標公共
(Get Rating)
(獲取評級)
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It offers clinical development services, including early development, patient recruitment and retention, strategy and analytics, late phase research, data and technology solution, and consulting and analytics services. The company's clinical development services also comprise medical imaging, clinical research and laboratory services, project management, site monitoring and management services, data management, biostatistics and programming, medical writing and publishing, medical affair, endpoint adjudication/data monitoring committees, pharmacovigilance, interactive response technologies, clinical supplies management, strategic regulatory, medical communication, and consulting and advisory services. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. The company was incorporated in 1990 and is headquartered in Dublin, Ireland.
ICON公共有限公司是一家臨牀研究機構,在愛爾蘭、歐洲其他地區、美國和國際上提供外包開發和商業化服務。該公司專門從事項目的戰略開發、管理和分析,這些項目支持從化合物選擇到I-IV階段臨牀研究的臨牀開發過程的各個階段。它提供臨牀開發服務,包括早期開發、患者招募和保留、戰略和分析、後期研究、數據和技術解決方案以及諮詢和分析服務。該公司的臨牀開發服務還包括醫學成像、臨牀研究和實驗室服務、項目管理、現場監測和管理服務、數據管理、生物統計和編程、醫療寫作和出版、醫療事務、終點裁決/數據監測委員會、藥物警戒、互動反應技術、臨牀用品管理、戰略監管、醫療通信以及諮詢和諮詢服務。它服務於製藥、生物技術和醫療器械行業,以及政府和公共衞生組織。該公司成立於1990年,總部設在愛爾蘭都柏林。
Receive News & Ratings for bioAffinity Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bioAffinity Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
接受《生物親和技術日報》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊,接收最新新聞和分析師對BioAffity Technologies及相關公司的評級的每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧